Page last updated: 2024-09-05

dofequidar and cyclosporine

dofequidar has been researched along with cyclosporine in 5 studies

Compound Research Comparison

Studies
(dofequidar)
Trials
(dofequidar)
Recent Studies (post-2010)
(dofequidar)
Studies
(cyclosporine)
Trials
(cyclosporine)
Recent Studies (post-2010) (cyclosporine)
402530,5473,8026,558

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (60.00)18.2507
2000's2 (40.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Tsuruo, T1
Ford, PJ; Germann, UA; Harding, MW; Mason, VS; Shlyakhter, D1
Hanibuchi, M; Parajuli, P; Shrivastava, P; Sone, S; Tsuruo, T; Yano, S1
Aoki, J; Kimura, Y; Kohno, M; Nakanishi, O; Ooka, H; Tsuruo, T1
Hu, Y; Mizoi, K; Naitoh, Y; Sasajima, T; Satoh, T; Shimada, N; Takahashi, M1

Reviews

1 review(s) available for dofequidar and cyclosporine

ArticleYear
[Development of drugs to overcome drug resistance--basic approaches].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:3

    Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclosporine; Drug Resistance, Multiple; Humans; Leukemia P388; Leukemia, Myeloid; Mice; Mice, Nude; Quinolines; Tumor Cells, Cultured; Verapamil

1995

Other Studies

4 other study(ies) available for dofequidar and cyclosporine

ArticleYear
Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP.
    Anti-cancer drugs, 1997, Volume: 8, Issue:2

    Topics: Acridines; Affinity Labels; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Cyclosporine; Daunorubicin; Doxorubicin; Drug Resistance, Multiple; Etoposide; Fluoresceins; HL-60 Cells; Humans; Isoquinolines; Multidrug Resistance-Associated Proteins; Piperidines; Pyridines; Quinolines; Tetrahydroisoquinolines; Tritium; Verapamil; Vincristine

1997
Circumvention of multidrug resistance by a quinoline derivative, MS-209, in multidrug-resistant human small-cell lung cancer cells and its synergistic interaction with cyclosporin A or verapamil.
    Cancer chemotherapy and pharmacology, 1998, Volume: 42, Issue:6

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Small Cell; Cyclosporine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Humans; Lung Neoplasms; Quinolines; Tumor Cells, Cultured; Verapamil

1998
P-glycoprotein inhibition by the multidrug resistance-reversing agent MS-209 enhances bioavailability and antitumor efficacy of orally administered paclitaxel.
    Cancer chemotherapy and pharmacology, 2002, Volume: 49, Issue:4

    Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Caco-2 Cells; Cyclosporine; Cyclosporins; Humans; Male; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Paclitaxel; Quinolines; Rats; Rats, Sprague-Dawley

2002
(99m)Tc-MIBI imaging for prediction of therapeutic effects of second-generation MDR1 inhibitors in malignant brain tumors.
    International journal of cancer, 2007, Dec-15, Volume: 121, Issue:12

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Autoradiography; Brain Neoplasms; Carcinoma 256, Walker; Cell Line, Tumor; Cell Proliferation; Cyclosporine; Cyclosporins; Cytotoxins; Drug Resistance, Neoplasm; Drug Synergism; Predictive Value of Tests; Quinolines; Radiopharmaceuticals; Rats; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Technetium Tc 99m Sestamibi; Tomography, Emission-Computed, Single-Photon; Vincristine

2007